8-K: Bionano Genomics Q3 Revenue Jumps 21%, Margins Improve

Bionano Genomics reported a 21% increase in third-quarter 2025 revenue to $7.4 million, alongside significant improvements in gross margin and reduced operating expenses, validating its strategic shift.

Summary

• Total revenue for Q3 2025 was $7.4 million, representing a 21% increase from $6.1 million in Q3 2024.
• Consumables and software revenues increased by 15% in Q3 2025.
• Sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase over the 7,835 flowcells sold in Q3 2024.
• Installed 7 new OGM systems, bringing the total installed base to 384 at quarter-end, a 4% increase over the 368 systems reported at the end of Q3 2024.
• GAAP gross margin improved to 46% in Q3 2025 from (139)% in Q3 2024; non-GAAP gross margin was 46% compared to 26% in Q3 2024.
• Operating expenses decreased by 66% to $11.9 million, and non-GAAP operating expense decreased by 40% to $9.7 million.
• Ended Q3 2025 with $31.8 million in cash, cash equivalents, available-for-sale securities, and restricted short-term investments.
• Completed a public offering of common stock in September 2025, raising $10 million of aggregate gross proceeds.
• Reiterated full year 2025 revenue guidance in the range of $26.0 to $30.0 million.
• Initiated Q4 2025 revenue guidance in the range of $7.5 to $7.9 million.
• Expected new OGM system installations for full year 2025 to surpass 25, compared to prior expectations of 20 to 25.

Sentiment

Score: 7

Explanation: The filing indicates significant improvements in key financial metrics like revenue growth, gross margin, and operating expense reduction, validating a strategic shift. Increased OGM system installation guidance and positive clinical validation (CMS CPT code, publications) are strong positives. However, the company still reports a net loss and explicitly mentions risks related to its ability to continue as a going concern and the need for additional financing, tempering overall sentiment.

Positives

• Total revenue increased by 21% to $7.4 million in Q3 2025 compared to Q3 2024.
• Consumables and software revenues grew by 15%, indicating increased utilization among existing customers.
• GAAP gross margin significantly improved to 46% in Q3 2025 from (139)% in Q3 2024, and non-GAAP gross margin increased to 46% from 26%.
• Operating expenses were reduced by 66% to $11.9 million, demonstrating disciplined cost management.
• Increased nanochannel array flowcell sales by 7% to 8,390 units in Q3 2025.
• The installed base of OGM systems grew by 4% to 384 systems at quarter-end.
• Reported strong global momentum for OGM, including expanding utilization in new regions like Japan.
• The Centers for Medicare & Medicaid Services (CMS) posted a preliminary payment determination for the Category I Current Procedural Terminology (CPT) code for OGM, which could accelerate adoption.
• Multiple studies highlighting OGM utility for cancer biomarker analysis and acute leukemia were published, demonstrating growing scientific validation.
• Increased full year 2025 OGM system installation guidance to surpass 25, up from prior expectations of 20 to 25.

Negatives

• Reported a net loss of $(8.5) million for Q3 2025 and $(18.5) million for the nine months ended September 30, 2025.
• Cash, cash equivalents, available-for-sale securities, and restricted short-term investments decreased to $31.8 million at quarter-end from $39.489 million at December 31, 2024.
• Total revenue for the nine months ended September 30, 2025, decreased to $20.557 million from $22.613 million in the same period of 2024.

Risks

• Ability to improve margins, extend cash runway, and reach a potential pathway to profitability.
• Ability to continue as a going concern within 12 months, which requires managing costs and obtaining significant additional financing.
• Ability to execute on strategy and achieve objectives.
• The impact and utility of cost savings initiatives and recent financing.
• Ability to continue driving OGM adoption by potential customers for routine use in genomic analysis.
• The impact, or lack thereof, of Category I CPT codes to accelerate or increase the adoption of OGM.
• Ability to manage the growth of the business and integrate acquired businesses.
• Ability to expand the commercial organization to address effectively existing and new markets.
• Impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries.
• Ability to compete effectively in a competitive industry, including the introduction of competitive technologies or improvements in existing technologies.
• The performance of third-party contract sales organizations, suppliers, and manufacturers.
• Ability to attract and retain key scientific or management personnel.
• Accuracy of estimates regarding expenses, future revenues, reimbursement rates, capital requirements, and needs for additional financing.
• The impact of adverse geopolitical and macroeconomic developments, such as bank failures, ongoing conflicts, pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions, on business and operations.
• Ability to realize the anticipated benefits and synergies of prior and any future acquisitions or other strategic transactions.
• Ability to attract collaborators and strategic partnerships.

Future Outlook

Bionano Genomics reiterates its full year 2025 revenue guidance in the range of $26.0 to $30.0 million and initiates Q4 2025 revenue guidance between $7.5 million and $7.9 million. The company also expects new OGM system installations for the full year 2025 to surpass 25, an increase from previous expectations of 20 to 25, indicating continued growth in its installed base.

Management Comments

• "Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers."
• "Our performance in the third quarter and year-to-date validates this strategic shift and demonstrates our turn toward sustainable growth as our business stabilizes."
• "This quarter we delivered sustained margins, disciplined operating expense management, and increased utilization from routine users."
• "We continue to see strong momentum in our key geographies and expanding utilization in new regions, including Japan, where researchers are leveraging optical genome mapping (OGM) to address complex questions in genetics."
• "These developments strengthen our confidence in Bionanos long-term growth trajectory."

Industry Context

The announcement highlights the growing adoption and utility of Optical Genome Mapping (OGM) in the genomics and diagnostics industry, particularly for addressing complex questions in genetics, cancer biomarker analysis, and acute leukemia. The preliminary payment determination for the Category I CPT code for OGM by CMS is a significant development, potentially accelerating OGM's integration into routine clinical cytogenomic analysis, positioning it as a strong alternative or complement to traditional cytogenetics and targeted RNA-Sequencing.

Comparison to Industry Standards

• OGM is shown to overcome key limitations of targeted RNA-Sequencing for cytogenetic investigation in acute leukemia, representing the first comparison of OGM and RNA-sequencing in cancer.
• OGM's utility for genome-wide analysis to detect structural and copy number variations relative to constitutional genetic disorders is being recognized by CMS with a preliminary payment determination for a Category I CPT code, suggesting a move towards broader clinical acceptance compared to traditional methods.
• The company's focus on driving consumables and software utilization among existing routine use customers aligns with a common strategy in the life sciences tools industry to build recurring revenue streams, similar to companies like Illumina or Thermo Fisher Scientific with their instrument and reagent models.

Stakeholder Impact

• Shareholders: Positive impact from improved financial performance (revenue, margins, reduced expenses) and strategic validation, but diluted by the recent $10 million capital raise and ongoing concerns about profitability and future financing needs.
• Customers/Researchers/Clinicians: Positive impact from increased OGM utility, new publications, and the preliminary CMS payment determination for a CPT code, which could facilitate broader adoption and reimbursement for OGM-based diagnostic testing.
• Employees: The prior year's non-GAAP adjustments mention restructuring expenses, implying past impact, but no current changes are detailed.

Next Steps

• Continue driving consumables and software utilization among existing routine use customers.
• Leverage global momentum and expanding utilization in new regions.
• Monitor the impact of the CMS preliminary payment determination for the Category I CPT code for OGM.
• Continue research, presentations, and publications involving OGM.
• Execute on the strategy to improve margins, extend cash runway, and achieve profitability.

Key Dates

Recommendation

Bionano Genomics demonstrated strong operational improvements in Q3 2025, with a 21% revenue increase, a significant turnaround in gross margin to 46%, and a 66% reduction in operating expenses. The strategic shift towards consumables and software utilization appears to be gaining traction, supported by increased OGM system installations and positive clinical validation, including a preliminary CMS CPT code determination. However, the company continues to report a net loss and explicitly highlights its ability to continue as a going concern and the need for significant additional financing as key risks. While the operational trajectory is positive, the ongoing financial challenges and the recent capital raise suggest a 'hold' recommendation. Investors should monitor the company's progress towards profitability and its ability to secure future funding without excessive dilution, as well as the market adoption rate of OGM following the CPT code development.

Keywords

Bionano Genomics, Optical Genome Mapping, OGM, Genomics, Biotechnology, Financial Results, Q3 2025, Revenue Growth, Gross Margin, Operating Expenses, Consumables, Software, Flowcells, Installed Base, CPT Code, ASHG, Cancer Biomarkers, Acute Leukemia, Diagnostics, Life Sciences